Internationalisation of pharmaceutical R&D: How globalised are Europe's largest multinational companies?

Technology Analysis and Strategic Management

Volumn 21, Issue 7, 2009, Pages 859-879

  Tijssen, Robert J W ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Bibliometrics; Business and management studies; Europe; Pharmaceutical industry; Quantitative; Technology and innovation studies

Indexed keywords

BIOTECHNOLOGY; CORPORATE STRATEGY; DECISION MAKING; GLOBALIZATION; HIGH TECHNOLOGY INDUSTRY; INNOVATION; METHODOLOGY; MULTINATIONAL ENTERPRISE; QUANTITATIVE ANALYSIS; RESEARCH AND DEVELOPMENT; SCIENCE AND TECHNOLOGY; STRATEGIC APPROACH;

EUROPE;

EID: 74949092802     PISSN: 09537325     EISSN: 14653990     Source Type: Journal    
DOI: 10.1080/09537320903182330     Document Type: Article

References (42)

1. Abramovsky, L., R. Harrison, and H. Simpson. 2006. University research and the location of business R&D. Institute for Fiscal Studies Report WP07/02, London.
2. Archibugi, D., and J. Michie. 1995. The globalization of technology - a new taxonomy. Cambridge Journal of Economics 19: 121-40.
3. Arundel,A., andA. Geuna. 2004. Proximity and the use of public science by innovative European companies. Economics of Innovation and New Technology 13: 559-80.
4. Beise, M. 2004. Lead markets: country-specific drivers of the global diffusion of innovations. Research Policy 33: 997-1018.
5. Bower, D. 1993. New technology supply networks in the global pharmaceutical industry. International Business Review 2: 83-95.
6. Calero, C., T.N. Van Leeuwen, and R.J.W. Tijssen. 2007. Research cooperation within the bio-pharmaceutical industry: network analyses of co-publications within and between companies. Scientometrics 71: 87-99.
7. Cantell, J. 1991. The international agglomeration of R&D. In Global research strategy and international competitiveness, ed. M. Casson, 104-32. Oxford: Blackwell.
8. Cardinal, L., and D. Hatfield. 2000. Internal knowledge generation: the research laboratory and innovative productivity in the pharmaceutical industry. Journal of Engineering and Technology Management 17: 247-71.
9. Chan, P. 2006. All eyes on early-stage assets. The Scrip 100, 35-7.
10. Cockburn, I., and R. Henderson. 1996. Public-private interaction in pharmaceutical research. Proceedings of the National Academy of Sciences of the United States of America 93: 12725-30.
11. Coombs, R., and J. Metcalfe. 2002. Innovation in pharmaceutical perspectives on the co-ordination, combination and creation of capabilities. Technology Analysis & Strategic Management 14: 261-72.
12. Criscuolo, P., and R. Narula. 2007. Using multi-hub structures for international R&D: organizational inertia and the challenges of implementation. Management International Review 46: 639-60.
13. Drews, J. 1989. Research in the pharmaceutical industry. European Management Journal 7: 23-30.
14. DTI. 2006. Universities enhance competitiveness and quality of life in the UK. Report by UK Department of Trade & Industry and Higher Education Funding Council for England, London.
15. EC. 2005. EU industrial R&D investment scoreboard - Vol. II. Brussels: European Commission.
16. EFPIA. 2006. The pharmaceutical industry in figures. Brussels: European Federation of Pharmaceutical Industries and Associations.
17. Gambardella,A. 1995. Science and innovation: the US pharmaceutical industry during the 1980s. Cambridge: Cambridge University Press.
18. Gassman, O., and M. Von Zedtwitz. 1999. New concepts and trends in international R&D. Research Policy 28: 231-50.
19. Gassman, O., and G. Reepmeyer. 2005. Organizing pharmaceutical innovation: from science-based knowledge creators to drug-oriented knowledge brokers. Creativity and Innovation Management 14: 233-45.
20. Hicks, D. 1995. Tacit competences and corporate management of the public/private character of knowledge. Industrial and Corporate Change 4: 401-24.
21. Jones, O. 2000. Innovation management as a post-modern phenomenon: the outsourcing of pharmaceutical R&D. British Journal of Management 11: 341-56.
22. Kettler, H. 2001. The role of the external network in the pharmaceutical R&D process: alliances and licensing strategies. In Consolidation and competition in the pharmaceutical industry, ed. H. Kettler, 106-17. London: Office of Health Economics.
23. Koenig, M. 1983. A bibliometric analysis of pharmaceutical research. Research Policy 12: 15-36.
24. Kuemmerle, W. 1999. Foreign direct investment in industrial research in the pharmaceutical and electronics: results from a survey of multinational firms. Research Policy 28: 179-93.
25. McKelvey, M., L. Orsenigo, and F. Pammolli. 2004. Pharmaceuticals analysed through the lens of a sectoral innovation system. In Sectoral systems of innovation, ed. F. Malerba, 73-120. Cambridge: Cambridge University Press.
26. McMillan, G., and R. Hamilton. 2000. Using bibliometrics to measure company knowledge: an analysis of the US pharmaceutical industry. Technology Analysis and Strategic Management 12: 465-75.
27. Narin, F., and R. Rozek. 1988. Bibliometric analysis of bibliometric analysis of United States pharmaceutical industry research performance. Research Policy 17: 139-54.
28. OECD. 2005. Handbook on economic globalisation indicators. Paris: Organisation of Economic Cooperation and Development.
29. Orsenigo, L., F. Pammolli, and M. Riccaboni. 2001. Technological change and network dynamics lessons from the pharmaceutical industry. Research Policy 30: 485-508.
30. Patel, P., and K. Pavitt. 1991. Large firms in the production of the world's technology - an important case of non- globalization. Journal of International Business Studies 22: 1-21.
31. Pisano, G., W. Shan, and D. Teece. 1988. Joint ventures and collaboration in the biotechnology industry. In International collaborative ventures in US manufacturing, ed. D. Mowery. 183-222. Cambridge: Ballinger.
32. Powell, W. 1998. Learning from collaboration: knowledge and networks in the biotechnology and pharmaceutical industries. California Management Review 40: 228-40.
33. Roijakkers, N., and J. Hagedoorn. 2005. Inter-company R&D partnering in pharmaceutical biotechnology since 1975: trends, patterns, and networks. Research Policy 35: 431-46.
34. Rugman, A., and C. Brain. 2004. Regional strategies of multinational pharmaceutical firms. Management International Review 44: 7-25.
35. PWC. 2007. Pharma 2020: the vision - which path will you take? Report by PriceWaterhouseCoopers. http://www.pwc.com (accessed 18 June 2007).
36. Tapon, F., and M. Thong. 1999. Research collaborations by multinational research oriented pharmaceutical firms: 1988-1997. R&D Management 29: 219-31.
37. Tijssen, R.J.W. 2004. Is the commercialisation of scientific research affecting the production of public knowledge? Global trends in the output of corporate research articles. Research Policy 33: 709-33.
38. Tijssen, R.J.W. 2006. International benchmarking of research performance in clinical pharmacology. Report to Netherlands Association of Research-based Pharmaceutical Industries (NEFARMA), The Hague.
39. Thursby, J., and M. Thursby. 2006. Where is the new science in corporate R&D? Science 314: 1547-448.
40. Walsh, V., and I. Galimberti. 1993. Firm strategies, globalisation and new technological paradigms: the case of biotechnology. In The impact of globalisation on Europe's firms and industries, ed. M. Humbert, 175-90. London: Pinter.
41. Walsh, V., and G. Lodorfos. 2002. Technological and organisational innovation in chemicals and related products. Technology Analysis & Strategic Management 14: 273-98.
42. Whittaker, E., and D. Bower. 1994. A shift to external alliances for product development in the pharmaceutical industry. R&D Management 24: 249-60.